Beam Therapeutics Inc.
Records under this name other than the patents Beam Therapeutics Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 21 patents it holds.
Back to Beam Therapeutics Inc.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,795,443 | Uses of Adenosine Base Editors now held by The Broad Institute, Inc. In force · High confidence | In force | High confidence | |
| US 12,594,301 | Compositions and Methods for Treatment of Liquid Cancers now held by Ucl Business Ltd. In force · High confidence | In force | High confidence | |
| 17/054,348 | Methods of Editing Single Nucleotide Polymorphism Using Programmable Base Editor Systems Pending Term is not computable until grant, so no date is shown and no estimate is implied. | Pending | Term is not computable until grant, so no date is shown and no estimate is implied. | |
| 17/054,393 | Methods of Suppressing Pathogenic Mutations Using Programmable Base Editor Systems Pending Term is not computable until grant, so no date is shown and no estimate is implied. | Pending | Term is not computable until grant, so no date is shown and no estimate is implied. | |
| 17/265,440 | Multi-Effector Nucleobase Editors and Methods of Using Same to Modify a Nucleic Acid Target Sequence Pending Term is not computable until grant, so no date is shown and no estimate is implied. | Pending | Term is not computable until grant, so no date is shown and no estimate is implied. | |
| 17/423,428 | Modified Immune Cells Having Enhanced Anti-Neoplasia Activity and Immunosuppression Resistance Pending Term is not computable until grant, so no date is shown and no estimate is implied. | Pending | Term is not computable until grant, so no date is shown and no estimate is implied. | |
| 17/430,274 | Compositions and Methods for Treating Glycogen Storage Disease Type 1A Pending Term is not computable until grant, so no date is shown and no estimate is implied. | Pending | Term is not computable until grant, so no date is shown and no estimate is implied. | |
| 17/430,289 | Splice Acceptor Site Disruption of a Disease-Associated Gene Using Adenosine Deaminase Base Editors, Including for the Treatment of Genetic Disease Pending Term is not computable until grant, so no date is shown and no estimate is implied. | Pending | Term is not computable until grant, so no date is shown and no estimate is implied. | |
| 17/430,298 | Compositions and Methods for Treating Hemoglobinopathies Pending Term is not computable until grant, so no date is shown and no estimate is implied. | Pending | Term is not computable until grant, so no date is shown and no estimate is implied. | |
| 17/430,669 | Adenosine Deaminase Base Editors and Methods of Using Same to Modify a Nucleobase in a Target Sequence Pending Term is not computable until grant, so no date is shown and no estimate is implied. | Pending | Term is not computable until grant, so no date is shown and no estimate is implied. |